Skip to main content
Equibles

Daniel Antalfi

Analyst

UBS

Equibles does not estimate personal net worth.

About Daniel Antalfi

Daniel Antalfi is recorded as Analyst at UBS. Daniel Antalfi has spoken on 7 earnings calls across 7 companies, most recently for Tandem Diabetes Care Inc on February 19, 2026. Those appearances were for Tandem Diabetes Care Inc (TNDM), Inspire Medical Systems, Inc. (INSP), Zimmer Biomet Holdings, Inc. (ZBH), Boston Scientific Corp (BSX), Stryker Corp (SYK) and 2 other companies. The companies whose calls Daniel Antalfi spoke on are classified in the Healthcare sector.

Daniel Antalfi on recent calls

“I guess we just on the leverage that was really nice to see in the quarter. Good to see in the guidance and the commitment to that. I'm just curious what the different levers are here.”
Analyst — UBS, Tandem Diabetes Care Inc Q4 FY2025 Earnings Call ·
“Sorry, I don't know what's going on today, but technology is not my friend. So I am sorry about that. Thank you guys so much for taking the question. Appreciate a lot of this call has been about reimbursement and impact there.”
Analyst — UBS, Inspire Medical Systems, Inc. Q4 FY2025 Earnings Call ·
“Just on this Salesforce transition, I'm just curious sort of what gives you the confidence. I appreciate a third has been done so far. But just coming to the decision to make this move, was it best practices at competitors, market research, physician feedback?”
Analyst — UBS, Zimmer Biomet Holdings, Inc. Q4 FY2025 Earnings Call ·
“And, Mike, sorry, this is another EP Watchman question. And maybe it's actually for Dr. Stein, though. So, I mean, I guess I'm curious, as you see competitors launch, I know you guys talked about, like, pretty significant efficiency gains with TheraPulse and PFA devices overall.”
Analyst — UBS, Boston Scientific Corp Q4 FY2025 Earnings Call ·

Affiliation history

  • UBS

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity